Actavis Inc (ACT) 295.22 $ACT
15 'Sustainable' Companies Not Named Apple to Buy Right Now
at The Street - Wed Apr 22, 3:45PM CDT
American companies topped the list of global corporate sustainability leaders in 2015, but are they good investments? We take a look on earth day 2015.
KO: 41.31 (+0.53), BIIB: 423.57 (+1.46), ACT: 295.22 (+0.69), GE: 26.91 (+0.29), A: 42.71 (-0.18), INTC: 32.70 (+0.27), ADBE: 75.50 (+0.88), JNJ: 100.43 (+0.13), SIAL: 138.92 (+0.17), CPB: 46.11 (+0.06), GIS: 56.21 (+0.10), CSCO: 28.62 (-0.07), CL: 69.28 (+0.27), ECL: 116.05 (+0.17), JCI: 51.33 (+0.30)
Teva Proposes to Buy Mylan, Sends Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 1:11PM CDT
Teva (TEVA) made an offer to acquire Mylan (MYL) for $82 per share in a deal that would create a powerhouse of generics with revenues of more than $30 billion.
ACT: 295.22 (+0.69), PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)
Orexigen Faces Generic Challenge For Anti-Obesity Drug
Spencer Osborne - at Seeking Alpha - Wed Apr 22, 11:24AM CDT
OREX: 7.39 (+0.22), ACT: 295.22 (+0.69), VVUS: 2.50 (+0.04)
Teva offers to buy Mylan in $40.1B cash-and-stock deal
By LINDA A. JOHNSON - AP - Tue Apr 21, 4:30PM CDT
TRENTON, N.J. (AP) — Generic drug giant Teva formally offered to buy fellow drugmaker Mylan for about $40.1 billion in cash and stock on Tuesday, despite Mylan's cold shoulder and the certainty the proposed acquisition will bring intense scrutiny by antitrust regulators.
AGN: 240.22 (+2.88), ACT: 295.22 (+0.69), ASPX: 100.79 (+0.09), TEVA: 63.01 (-1.15)
Actavis' Botox Upper Limb Spasticity Label Expanded by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 3:08PM CDT
Actavis' (ACT) Botox has been granted further FDA approval; adds upper limb spasticity to its label.
CRMD: 8.86 (-0.28), BIIB: 423.57 (+1.46), ACT: 295.22 (+0.69), AVEO: 2.04 (+0.12)
Pharma Spends Big On M&A In Q1 As Teva Pulls Trigger On Mylan
EP Vantage - Seeking Alpha - Tue Apr 21, 2:25PM CDT
The pharma and biotech buying spree showed no sign of abating in the opening months of 2015, with $69bn committed across 62 deals in the first quarter, EvaluatePharma data show. And with Teva (NYSE: TEVA ) confirming its interest in ...
AGN: 240.22 (+2.88), VRX: 206.93 (-3.92), ACT: 295.22 (+0.69), PFE: 34.93 (+0.04), MYL: 72.40 (-1.67), ABBV: 64.52 (+0.91), TEVA: 63.01 (-1.15)
Actavis reports planned departure of chief communications officer Charles M Mayr
M2 - Tue Apr 21, 7:31AM CDT
Pharmaceutical company Actavis plc (NYSE:ACT) revealed on Monday the retirement of its chief communications officer, Charles M Mayr due to health reasons.
ACT: 295.22 (+0.69)
Actavis Announces Retirement of Charles M. Mayr
PR Newswire - Mon Apr 20, 3:15PM CDT
Actavis plc (NYSE: ACT) today announced that Charles M. Mayr, Chief Communications Officer, will retire from Actavis on May 15, 2015 due to health reasons. In conjunction with Mayr's retirement, Alex Kelly, Chief Integration Officer, will assume the role of Chief Communications Officer, effective immediately. Prior to joining Actavis in 2014, Kelly served as Senior Vice President, Chief Communications Officer, Public Affairs and Investor Relations at Forest Laboratories.
ACT: 295.22 (+0.69)
Actavis Announces FDA Approval of Expanded Label for BOTOX® (OnabotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Adults
PR Newswire - Mon Apr 20, 7:00AM CDT
Actavis plc (NYSE: ACT), which recently completed the acquisition of Allergan, today announced that the United States Food and Drug Administration (FDA) has approved an expansion of the BOTOX® (onabotulinumtoxinA) label for the treatment of adults with upper limb spasticity. The expanded label now includes the addition of two thumb muscles: flexor pollicis longus, a muscle in the forearm that flexes the thumb; and adductor pollicis, a muscle in the hand that functions to adduct the thumb; increasing the maximum dose from 360 to 400 units for the treatment of upper limb spasticity. The FDA also approved an increase to the maximum BOTOX® cumulative dose within three months from 360 to 400 units in adults treated for one or more indications.
AGN: 240.22 (+2.88), ACT: 295.22 (+0.69)
Global Worries Sink U.S. Stocks; Apple Breaches Support Level
at Investor's Business Daily - Fri Apr 17, 3:37PM CDT
Stocks closed sharply lower, though off their worst levels of the day, as concerns about Greece and new Chinese regulations weighed throughout the session. The Nasdaq and Dow Jones industrial average each sank 1.5%, while the S&P 500 gave up 1.1%....
ACT: 295.22 (+0.69), AKRX: 53.70 (-1.69), MYL: 72.40 (-1.67), FLTX: 47.90 (+0.56), ATHM: 52.09 (+0.08), LCI: 66.45 (-0.28), PNK: 36.10 (-0.13), NOW: 77.72 (+0.22), MAT: 28.36 (+1.14), TEVA: 63.01 (-1.15), AAPL: 128.62 (+1.71), UVE: 25.49 (+0.38)
Revenue Weakness Stands Out in Q1 Earnings Season - Earnings Preview
Sheraz Mian - Zacks Investment Research - Fri Apr 17, 3:06PM CDT
Revenue Weakness Stands Out in Q1 Earnings Season - Earnings Preview
AMZN: 389.80 (-1.38), ACT: 295.22 (+0.69), STT: 77.93 (+1.26), FB: 84.63 (+1.01), HAL: 47.11 (+0.06), BAC: 15.74 (+0.24), BA: 151.19 (-2.14), MS: 37.20 (+0.45), YHOO: 43.97 (-0.52), T: 32.86 (+0.20), LYB: 97.11 (+0.56), GILD: 104.18 (-1.02), DD: 71.44 (+0.75), MCD: 97.84 (+2.97), GM: 37.16 (unch), GOOGL: 549.18 (+6.26), CAT: 84.87 (+0.95), PG: 83.09 (+0.01), MSFT: 42.99 (+0.36), DOW: 50.02 (+0.37), VZ: 49.57 (+0.40)
5 Must-See Stock Charts to Trade for Gains
at The Street - Thu Apr 16, 9:05AM CDT
Here's a look at how to trade some of the biggest stocks on Wall Street.
JNJ: 100.43 (+0.13), ACT: 295.22 (+0.69), AMGN: 169.10 (+0.64), BNS: 54.41 (+0.21), BABA: 82.05 (-0.37)
Teva, Actavis, Other Generic Drugmakers May Be on Acquisition Trail
at The Street - Thu Apr 16, 9:04AM CDT
Mylan's deal to buy Perrigo is taking another potential target off the block.
ABT: 48.35 (+1.23), PRGO: 201.50 (+8.68), ACT: 295.22 (+0.69), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15), ASPX: 100.79 (+0.09), NVS: 103.45 (-0.62)
Actavis to Host First Quarter 2015 Earnings Conference Call and Webcast
PR Newswire - Thu Apr 16, 8:00AM CDT
Actavis plc (NYSE: ACT) today announced that it intends to release first quarter 2015 financial results on Monday, May 11, 2015, prior to the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:00 a.m. Eastern Time on Monday, May 11, 2015 to discuss its financial results. The dial-in number to access the call is U.S./Canada (877) 251-7980, International (706) 643-1573, and the Passcode is 29079446.
ACT: 295.22 (+0.69)
Teva, Actavis, Other Giants Set to Battle for Generics Space
at The Street - Wed Apr 15, 10:30AM CDT
Teva, Actavis and other generics giants may start preying on each other.
ACT: 295.22 (+0.69), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15), NVS: 103.45 (-0.62)
How To Buy A Rising Market Leader On A Pullback
at Investor's Business Daily - Tue Apr 14, 4:03PM CDT
A market leader will usually offer multiple chances to get on board and build a position in its stock. One of the last favorable opportunities is a leading stock's second trip to the 10-week moving average after a breakout. First, let's define how...
ACT: 295.22 (+0.69)
Progress At Synergy Pharmaceuticals, But Not Enough To Really Please Investors
Stephen Simpson, CFA - at Seeking Alpha - Tue Apr 14, 3:04PM CDT
SGYP: 4.01 (-0.06), ACT: 295.22 (+0.69), IRWD: 15.07 (-0.19)
Paratek Pharmaceuticals: The Next Blockbuster Antibiotic At A Third Of The Valuation
Bridging the Gap - at Seeking Alpha - Tue Apr 14, 1:09PM CDT
ACT: 295.22 (+0.69), PRTK: 28.96 (+0.61)
Parents sue Botox maker after woman with cerebral palsy dies
The Burlington Free Press - Tue Apr 14, 12:27PM CDT
BURLINGTON, Vt. (AP) — The parents of a Vermont woman who died last year have sued Botox maker Allergan, saying treatment of her cerebral palsy with Botox contributed to her death.
ACT: 295.22 (+0.69)
15 'Sustainable' Companies Not Named Apple to Buy Right Now
at The Street - Wed Apr 22, 3:45PM CDT
American companies topped the list of global corporate sustainability leaders in 2015, but are they good investments? We take a look on earth day 2015.
KO: 41.31 (+0.53), BIIB: 423.57 (+1.46), ACT: 295.22 (+0.69), GE: 26.91 (+0.29), A: 42.71 (-0.18), INTC: 32.70 (+0.27), ADBE: 75.50 (+0.88), JNJ: 100.43 (+0.13), SIAL: 138.92 (+0.17), CPB: 46.11 (+0.06), GIS: 56.21 (+0.10), CSCO: 28.62 (-0.07), CL: 69.28 (+0.27), ECL: 116.05 (+0.17), JCI: 51.33 (+0.30)
Teva Proposes to Buy Mylan, Sends Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 1:11PM CDT
Teva (TEVA) made an offer to acquire Mylan (MYL) for $82 per share in a deal that would create a powerhouse of generics with revenues of more than $30 billion.
ACT: 295.22 (+0.69), PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)
Orexigen Faces Generic Challenge For Anti-Obesity Drug
Spencer Osborne - at Seeking Alpha - Wed Apr 22, 11:24AM CDT
OREX: 7.39 (+0.22), ACT: 295.22 (+0.69), VVUS: 2.50 (+0.04)
Teva offers to buy Mylan in $40.1B cash-and-stock deal
By LINDA A. JOHNSON - AP - Tue Apr 21, 4:30PM CDT
TRENTON, N.J. (AP) — Generic drug giant Teva formally offered to buy fellow drugmaker Mylan for about $40.1 billion in cash and stock on Tuesday, despite Mylan's cold shoulder and the certainty the proposed acquisition will bring intense scrutiny by antitrust regulators.
AGN: 240.22 (+2.88), ACT: 295.22 (+0.69), ASPX: 100.79 (+0.09), TEVA: 63.01 (-1.15)
Actavis' Botox Upper Limb Spasticity Label Expanded by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 3:08PM CDT
Actavis' (ACT) Botox has been granted further FDA approval; adds upper limb spasticity to its label.
CRMD: 8.86 (-0.28), BIIB: 423.57 (+1.46), ACT: 295.22 (+0.69), AVEO: 2.04 (+0.12)
Pharma Spends Big On M&A In Q1 As Teva Pulls Trigger On Mylan
EP Vantage - Seeking Alpha - Tue Apr 21, 2:25PM CDT
The pharma and biotech buying spree showed no sign of abating in the opening months of 2015, with $69bn committed across 62 deals in the first quarter, EvaluatePharma data show. And with Teva (NYSE: TEVA ) confirming its interest in ...
AGN: 240.22 (+2.88), VRX: 206.93 (-3.92), ACT: 295.22 (+0.69), PFE: 34.93 (+0.04), MYL: 72.40 (-1.67), ABBV: 64.52 (+0.91), TEVA: 63.01 (-1.15)
Actavis reports planned departure of chief communications officer Charles M Mayr
M2 - Tue Apr 21, 7:31AM CDT
Pharmaceutical company Actavis plc (NYSE:ACT) revealed on Monday the retirement of its chief communications officer, Charles M Mayr due to health reasons.
ACT: 295.22 (+0.69)
Actavis Announces Retirement of Charles M. Mayr
PR Newswire - Mon Apr 20, 3:15PM CDT
Actavis plc (NYSE: ACT) today announced that Charles M. Mayr, Chief Communications Officer, will retire from Actavis on May 15, 2015 due to health reasons. In conjunction with Mayr's retirement, Alex Kelly, Chief Integration Officer, will assume the role of Chief Communications Officer, effective immediately. Prior to joining Actavis in 2014, Kelly served as Senior Vice President, Chief Communications Officer, Public Affairs and Investor Relations at Forest Laboratories.
ACT: 295.22 (+0.69)
Actavis Announces FDA Approval of Expanded Label for BOTOX® (OnabotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Adults
PR Newswire - Mon Apr 20, 7:00AM CDT
Actavis plc (NYSE: ACT), which recently completed the acquisition of Allergan, today announced that the United States Food and Drug Administration (FDA) has approved an expansion of the BOTOX® (onabotulinumtoxinA) label for the treatment of adults with upper limb spasticity. The expanded label now includes the addition of two thumb muscles: flexor pollicis longus, a muscle in the forearm that flexes the thumb; and adductor pollicis, a muscle in the hand that functions to adduct the thumb; increasing the maximum dose from 360 to 400 units for the treatment of upper limb spasticity. The FDA also approved an increase to the maximum BOTOX® cumulative dose within three months from 360 to 400 units in adults treated for one or more indications.
AGN: 240.22 (+2.88), ACT: 295.22 (+0.69)
Global Worries Sink U.S. Stocks; Apple Breaches Support Level
at Investor's Business Daily - Fri Apr 17, 3:37PM CDT
Stocks closed sharply lower, though off their worst levels of the day, as concerns about Greece and new Chinese regulations weighed throughout the session. The Nasdaq and Dow Jones industrial average each sank 1.5%, while the S&P 500 gave up 1.1%....
ACT: 295.22 (+0.69), AKRX: 53.70 (-1.69), MYL: 72.40 (-1.67), FLTX: 47.90 (+0.56), ATHM: 52.09 (+0.08), LCI: 66.45 (-0.28), PNK: 36.10 (-0.13), NOW: 77.72 (+0.22), MAT: 28.36 (+1.14), TEVA: 63.01 (-1.15), AAPL: 128.62 (+1.71), UVE: 25.49 (+0.38)
Revenue Weakness Stands Out in Q1 Earnings Season - Earnings Preview
Sheraz Mian - Zacks Investment Research - Fri Apr 17, 3:06PM CDT
Revenue Weakness Stands Out in Q1 Earnings Season - Earnings Preview
AMZN: 389.80 (-1.38), ACT: 295.22 (+0.69), STT: 77.93 (+1.26), FB: 84.63 (+1.01), HAL: 47.11 (+0.06), BAC: 15.74 (+0.24), BA: 151.19 (-2.14), MS: 37.20 (+0.45), YHOO: 43.97 (-0.52), T: 32.86 (+0.20), LYB: 97.11 (+0.56), GILD: 104.18 (-1.02), DD: 71.44 (+0.75), MCD: 97.84 (+2.97), GM: 37.16 (unch), GOOGL: 549.18 (+6.26), CAT: 84.87 (+0.95), PG: 83.09 (+0.01), MSFT: 42.99 (+0.36), DOW: 50.02 (+0.37), VZ: 49.57 (+0.40)
5 Must-See Stock Charts to Trade for Gains
at The Street - Thu Apr 16, 9:05AM CDT
Here's a look at how to trade some of the biggest stocks on Wall Street.
JNJ: 100.43 (+0.13), ACT: 295.22 (+0.69), AMGN: 169.10 (+0.64), BNS: 54.41 (+0.21), BABA: 82.05 (-0.37)
Teva, Actavis, Other Generic Drugmakers May Be on Acquisition Trail
at The Street - Thu Apr 16, 9:04AM CDT
Mylan's deal to buy Perrigo is taking another potential target off the block.
ABT: 48.35 (+1.23), PRGO: 201.50 (+8.68), ACT: 295.22 (+0.69), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15), ASPX: 100.79 (+0.09), NVS: 103.45 (-0.62)
Actavis to Host First Quarter 2015 Earnings Conference Call and Webcast
PR Newswire - Thu Apr 16, 8:00AM CDT
Actavis plc (NYSE: ACT) today announced that it intends to release first quarter 2015 financial results on Monday, May 11, 2015, prior to the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:00 a.m. Eastern Time on Monday, May 11, 2015 to discuss its financial results. The dial-in number to access the call is U.S./Canada (877) 251-7980, International (706) 643-1573, and the Passcode is 29079446.
ACT: 295.22 (+0.69)
Teva, Actavis, Other Giants Set to Battle for Generics Space
at The Street - Wed Apr 15, 10:30AM CDT
Teva, Actavis and other generics giants may start preying on each other.
ACT: 295.22 (+0.69), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15), NVS: 103.45 (-0.62)
How To Buy A Rising Market Leader On A Pullback
at Investor's Business Daily - Tue Apr 14, 4:03PM CDT
A market leader will usually offer multiple chances to get on board and build a position in its stock. One of the last favorable opportunities is a leading stock's second trip to the 10-week moving average after a breakout. First, let's define how...
ACT: 295.22 (+0.69)
Progress At Synergy Pharmaceuticals, But Not Enough To Really Please Investors
Stephen Simpson, CFA - at Seeking Alpha - Tue Apr 14, 3:04PM CDT
SGYP: 4.01 (-0.06), ACT: 295.22 (+0.69), IRWD: 15.07 (-0.19)
Paratek Pharmaceuticals: The Next Blockbuster Antibiotic At A Third Of The Valuation
Bridging the Gap - at Seeking Alpha - Tue Apr 14, 1:09PM CDT
ACT: 295.22 (+0.69), PRTK: 28.96 (+0.61)
Parents sue Botox maker after woman with cerebral palsy dies
The Burlington Free Press - Tue Apr 14, 12:27PM CDT
BURLINGTON, Vt. (AP) — The parents of a Vermont woman who died last year have sued Botox maker Allergan, saying treatment of her cerebral palsy with Botox contributed to her death.
ACT: 295.22 (+0.69)
